Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Phio Pharmaceuticals will present a clinical development update on its lead asset PH-762 at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania, on September 30 at 10:20 AM ET. CEO Robert Bitterman will recap the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, which showed a favorable safety profile, and outline next steps toward the program's next stage of development. The company states that activities supporting the next phase of PH-762 development, including planned FDA interactions, are expected to be completed during the first quarter of 2027.
Key figures
- Drug Name
- PH-762
- Phase Of Trial
- Phase 1b
- Presentation Date
- September 30, 2026, 10:20 AM ET
- Next Phase Activities Timing
- expected to be completed during Q1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.